# A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG

> **NCT03330197** · PHASE1,PHASE2 · TERMINATED · sponsor: **Alaunos Therapeutics** · enrollment: 6 (actual)

## Conditions studied

- Pediatric Brain Tumor
- Diffuse Intrinsic Pontine Glioma

## Interventions

- **BIOLOGICAL:** Ad-RTS-hIL-12
- **DRUG:** Oral Veledimex - Arm 1 (Pediatric Brain Tumor)
- **DRUG:** Oral Veledimex - Arm 2 (DIPG)

## Key facts

- **NCT ID:** NCT03330197
- **Lead sponsor:** Alaunos Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-26
- **Primary completion:** 2021-09-10
- **Final completion:** 2021-09-10
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Sponsor decision due to slow accrual
- **Last updated:** 2025-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03330197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03330197, "A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03330197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*